Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.

Johnston SS, Nguyen H, Cappell K, Nelson JK, Chu BC, Kalsekar I

Journal of medical economics12 Jun 2015Cited by 4 (Europe PMC)

PMID25867133DOI10.3111/13696998.2015.1039539PepBankPUB-25867133

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, in unadjusted exploratory analyses liraglutide patients had fewer median days supplied (124 days) than exenatide once weekly patients (141 days).
In plain wordsIn US adults with type 2 diabetes, people on liraglutide had fewer days of drug supplied during follow-up than people on exenatide once weekly.
Peptide
Liraglutide
Outcome
DecreaseDays supplied during follow-up
Study
n = 11,551
Comparator
Exenatide once weekly
Analysis
Exploratory
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Median days supplied
124 days
liraglutide
Median days supplied
141 days
exenatide QW
Source sentences
Summary
Unadjusted exploratory analyses showed that exenatide QW patients obtained a greater median number of days supplied for their GLP-1RA during follow-up (141 days) than liraglutide patients (124 days).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713307
02HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, liraglutide patients had higher odds of overall inpatient admission than exenatide once weekly patients (exenatide odds ratio 0.80).
In plain wordsIn US adults with type 2 diabetes, people starting liraglutide were more likely to have a hospital admission than people starting exenatide once weekly.
Peptide
Liraglutide
Outcome
IncreaseOverall inpatient admissions
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Odds ratio (exenatide QW versus liraglutide)
0.8 OR
overall inpatient admissions
Source sentences
Summary
In multivariable-adjusted analyses, compared with liraglutide patients, exenatide QW patients had statistically significantly lower odds of overall inpatient admissions (odds ratio [OR] = 0.80, p = 0.046)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713301
03HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, liraglutide patients had higher odds of diabetes-specific inpatient admission than exenatide once weekly patients (exenatide odds ratio 0.83).
In plain wordsIn US adults with type 2 diabetes, people starting liraglutide were more likely to have a diabetes-related hospital admission than people starting exenatide once weekly.
Peptide
Liraglutide
Outcome
IncreaseDiabetes-specific inpatient admissions
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Odds ratio (exenatide QW versus liraglutide)
0.83 OR
diabetes-specific inpatient admissions
Source sentences
Summary
and diabetes-specific (OR = 0.83, p = 0.026) inpatient admissions
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713302
04HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, overall total costs were similar between liraglutide ($8296) and exenatide once weekly ($7833; p = 0.069).
In plain wordsIn US adults with type 2 diabetes, overall total costs were similar for liraglutide and exenatide once weekly.
Peptide
Liraglutide
Outcome
No significant changeOverall total costs
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Overall total costs
8296 USD
liraglutide
Overall total costs
7833 USD
exenatide QW
Source sentences
Summary
similar overall total costs ($7833 exenatide QW, $8296 liraglutide, p = 0.069)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713303
05HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, diabetes-specific total costs were similar between liraglutide ($3736) and exenatide once weekly ($3610; p = 0.298).
In plain wordsIn US adults with type 2 diabetes, diabetes-related total costs were similar for liraglutide and exenatide once weekly.
Peptide
Liraglutide
Outcome
No significant changeDiabetes-specific total costs
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Diabetes-specific total costs
3736 USD
liraglutide
Diabetes-specific total costs
3610 USD
exenatide QW
Source sentences
Summary
diabetes-specific total costs ($3610 exenatide QW, $3736 liraglutide, p = 0.298)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713304
06HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, overall medical costs were significantly higher with liraglutide ($4652) than with exenatide once weekly ($3939; p = 0.008).
In plain wordsIn US adults with type 2 diabetes, overall medical costs were higher for liraglutide than for exenatide once weekly.
Peptide
Liraglutide
Outcome
IncreaseOverall medical costs
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Overall medical costs
4652 USD
liraglutide
Overall medical costs
3939 USD
exenatide QW
Source sentences
Summary
statistically significantly lower overall medical costs ($3939 exenatide QW, $4652 liraglutide, p = 0.008)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713305
07HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, diabetes-specific medical costs were significantly higher with liraglutide ($1469) than with exenatide once weekly ($1161; p = 0.007).
In plain wordsIn US adults with type 2 diabetes, diabetes-related medical costs were higher for liraglutide than for exenatide once weekly.
Peptide
Liraglutide
Outcome
IncreaseDiabetes-specific medical costs
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Measurements
Diabetes-specific medical costs
1469 USD
liraglutide
Diabetes-specific medical costs
1161 USD
exenatide QW
Source sentences
Summary
diabetes-specific medical costs ($1161 exenatide QW, $1469 liraglutide, p = 0.007)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713306
08HumanObservational studyOther
In commercially insured US adults with type 2 diabetes, sensitivity analyses by liraglutide dose (1.2 mg and 1.8 mg) were directionally consistent with the main comparison.
In plain wordsIn US adults with type 2 diabetes, results by liraglutide dose pointed the same way as the main comparison.
Peptide
Liraglutide
Outcome
Not applicableHealthcare use and costs by liraglutide dose
Study
n = 11,551
Comparator
Exenatide once weekly
Outcome group
Healthcare costs and utilization · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Sensitivity analyses assessing liraglutide by dose were directionally consistent.
3 context sentences(design, population, supporting numbers)
Summary · context
Sensitivity analyses were performed to assess liraglutide by dose (1.2 mg/1.8 mg).
Summary · context
This retrospective cohort study used US administrative claims data to study patients with T2DM initiating exenatide QW or liraglutide (initiated therapy = index therapy).
Summary · context
The study sample included 9106 liraglutide (4188, 1.2 mg; 4918, 1.8 mg) patients and 2445 exenatide QW patients.
Report a problemFND-2586713308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords